Choice of 2 Posters & one oral session presentation
David Goldstein, et al.:
Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC)
The autors of this study conclude that treatment arm, Karnofsky performance status (KPS), neutrophil-to-lymphocyte ratio (NLR), albumin level, sum of longest tumor diameters (SLD), and presence of liver metastasis were the key predictors of OS. This nomogram, which will be presented in visual format in the final presentation, may help physicians and pts make informed treatment decisions. Abstract
Sunil R. Hingorani,et al.:
Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
The autors of this study conclude that Randomized Phase II study met both primary endpoints (PFS and TE event rate), with the largest improvement in the secondary endpoint of PFS in HA-High pts. These data support HA as a potential predictive biomarker for patient selection of PEGPH20, currently investigated in the ongoing global Phase III HALO 301 study with PFS and OS as co-primary endpoints.
Davendra Sohal, et al.:
SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma
Dr. Hani M. Babiker, Assistant Professor of Medicine and Associate Director of Phase 1 Program, University of Arizona Comprehensive Cancer Center; Clinical Assistant Professor TGen comments about Highlights and News in Pancreatic Cancer:
Addition of Anti-CD38 Daratumumab to Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed MM
The study conclusion is that Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.